Rebecca Watters
YOU?
Author Swipe
View article: RNA-sequencing predicts a role of androgen receptor and aldehyde dehydrogenase 1A1 in osteosarcoma lung metastases
RNA-sequencing predicts a role of androgen receptor and aldehyde dehydrogenase 1A1 in osteosarcoma lung metastases Open
View article: Whole genome sequencing for metastatic mutational burden in extraskeletal myxoid chondrosarcoma
Whole genome sequencing for metastatic mutational burden in extraskeletal myxoid chondrosarcoma Open
Extraskeletal myxoid chondrosarcoma (EMC) is an ultra-rare cancer that makes up less than 3% of all soft tissue sarcomas. It most often arises in the soft tissues of the proximal limbs and has a higher incidence in males. Though EMC has a …
View article: Antioxidant 1 copper chaperone gene expression and copper levels in dog osteosarcoma patients
Antioxidant 1 copper chaperone gene expression and copper levels in dog osteosarcoma patients Open
Twenty‐four dogs with OS underwent limb amputation. Serum, OS tumour, and normal bone were harvested at time of surgery. RNA was extracted and gene expression was performed using quantitative polymerase chain reaction (qPCR). Tissue and bl…
View article: 133P Personalized circulating tumor DNA (ctDNA) during neoadjuvant therapy (NAT) to predict response in patients (pts) with early-stage breast cancer (eBC)
133P Personalized circulating tumor DNA (ctDNA) during neoadjuvant therapy (NAT) to predict response in patients (pts) with early-stage breast cancer (eBC) Open
View article: Supplementary Table S2 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption
Supplementary Table S2 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption Open
Consensus binding sequences for transcription factors
View article: Supplementary Figure S1 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption
Supplementary Figure S1 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption Open
Summary of gene expression changes following sulforaphane (SFN) treatment in breast cancer cells.
View article: Data from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer
Data from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer Open
DNA sequencing has identified a limited number of driver mutations in metastatic breast cancer beyond single base-pair mutations in the estrogen receptor (ESR1). However, our previous studies and others have observed that structural…
View article: Data from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer
Data from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer Open
DNA sequencing has identified a limited number of driver mutations in metastatic breast cancer beyond single base-pair mutations in the estrogen receptor (ESR1). However, our previous studies and others have observed that structural…
View article: Supplementary Figure S1 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption
Supplementary Figure S1 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption Open
Summary of gene expression changes following sulforaphane (SFN) treatment in breast cancer cells.
View article: Supplementary Figure S4 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption
Supplementary Figure S4 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption Open
Runt-related transcription factor 2 (RUNX2) occupancy at the promoter of matrix metallopeptidase 9 (MMP9).
View article: Supplementary Table S1 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption
Supplementary Table S1 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption Open
Correlation between genes altered by SFN treatment (TCGA BrCa dataset, n = 1097).
View article: Supplementary Figure S3 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption
Supplementary Figure S3 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption Open
Expression of runt-related transcription factor 2 (RUNX2) protein in luminal-type breast cancers and normal mammary tissues.
View article: Supplementary Tables 1-15 from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer
Supplementary Tables 1-15 from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer Open
Table S1. Clinicopathological characteristics and sample distribution by site Table S2. Primers/probes design for ddPCR (ESR1, EIF2C, AP3P1) Table S3. Raw nanoString counts Table S4. Normalized copy number calls (ER+ samples) Table S5. Nor…
View article: Supplementary Figure S2 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption
Supplementary Figure S2 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption Open
Sulforaphane (SFN) treatment downregulated expression of Runt-related transcription factor 2 (RUNX2) in SK-BR-3 cell line.
View article: Supplementary Table S1 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption
Supplementary Table S1 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption Open
Correlation between genes altered by SFN treatment (TCGA BrCa dataset, n = 1097).
View article: Supplementary Table S2 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption
Supplementary Table S2 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption Open
Consensus binding sequences for transcription factors
View article: Supplementary Figure S3 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption
Supplementary Figure S3 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption Open
Expression of runt-related transcription factor 2 (RUNX2) protein in luminal-type breast cancers and normal mammary tissues.
View article: Supplementary Figures 1-7 from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer
Supplementary Figures 1-7 from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer Open
Figure S1: Genomic organization of ESR1 nanoString probes Figure S2: Correlation of ESR1 amplification with mRNA expression Figure S3: ESR1 copy number status in ER+ primary-metastasis pairs Figure S4: Oncoprint visualization of copy numbe…
View article: Data from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption
Data from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption Open
Bone is the most preferred site for colonization of metastatic breast cancer cells for each subtype of the disease. The standard of therapeutic care for breast cancer patients with bone metastasis includes bisphosphonates (e.g., zoledronic…
View article: Supplementary Tables 1-15 from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer
Supplementary Tables 1-15 from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer Open
Table S1. Clinicopathological characteristics and sample distribution by site Table S2. Primers/probes design for ddPCR (ESR1, EIF2C, AP3P1) Table S3. Raw nanoString counts Table S4. Normalized copy number calls (ER+ samples) Table S5. Nor…
View article: Supplementary Figure S2 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption
Supplementary Figure S2 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption Open
Sulforaphane (SFN) treatment downregulated expression of Runt-related transcription factor 2 (RUNX2) in SK-BR-3 cell line.
View article: Supplementary Figure S4 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption
Supplementary Figure S4 from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption Open
Runt-related transcription factor 2 (RUNX2) occupancy at the promoter of matrix metallopeptidase 9 (MMP9).
View article: Supplementary Figures 1-7 from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer
Supplementary Figures 1-7 from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer Open
Figure S1: Genomic organization of ESR1 nanoString probes Figure S2: Correlation of ESR1 amplification with mRNA expression Figure S3: ESR1 copy number status in ER+ primary-metastasis pairs Figure S4: Oncoprint visualization of copy numbe…
View article: Data from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption
Data from A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer–Induced Osteolytic Bone Resorption Open
Bone is the most preferred site for colonization of metastatic breast cancer cells for each subtype of the disease. The standard of therapeutic care for breast cancer patients with bone metastasis includes bisphosphonates (e.g., zoledronic…
View article: Supplementary Figure from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
Supplementary Figure from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks Open
Supplementary Figure from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
View article: Supplementary Table from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
Supplementary Table from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks Open
Supplementary Table from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
View article: Supplementary Table from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
Supplementary Table from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks Open
Supplementary Table from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
View article: Supplementary Table from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
Supplementary Table from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks Open
Supplementary Table from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
View article: Supplementary Table from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
Supplementary Table from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks Open
Supplementary Table from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
View article: Supplementary Table from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
Supplementary Table from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks Open
Supplementary Table from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks